



UroGen Pharma to Present at Upcoming Investor Conferences

August 29, 2024

- H.C. Wainwright 26th Annual Global Investment Conference -

- 2024 Cantor Global Healthcare Conference -

PRINCETON, N.J.--(BUSINESS WIRE)--Aug. 29, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in fireside chats at the following investor conferences in September:

H.C. Wainwright 26th Annual Global Investment Conference – September 9-11th, 2024

Fireside Chat: September 9th, 2024 at 9:00am ET

Location: New York, NY

Webcast Registration Link: [Here](#)

2024 Cantor Global Healthcare Conference – September 17-19th, 2024

Fireside Chat: September 18, 2024 at 3:40pm ET

Location: New York, NY

Webcast Registration Link: [Here](#)

A webcast from the conference will also be available via the Investors section of UroGen's website, www.urogen.com. A replay of the webcast will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed *RTGel*® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240829971223/en/): <https://www.businesswire.com/news/home/20240829971223/en/>

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.